Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 59 cents. The ...

Reports Q4 revenue $$6.278M, consensus $16.58M.” Over the past year, Voyager has significantly advanced our two wholly-owned programs targeting ...

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELAN – Research ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...

VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: ...